Heart Failure Models In Vitro or In Vivo

TOPICAL COLLECTIONS

Guest Editor

Yihai Liu

Nanjing Medical University

Yihai Liu acquired a PhD and MD in Cardiology in Nanjing Medical University. He presently works in the Department of Cardiology of Nanjing Drum Tower Hospital. He has an interest in exploring the pathogenesis of cardiovascular diseases and the potential treatment in the future. His research fields include myocardial infarction, heart failure, cardiac toxicity and atherosclerosis. He has published the following articles: 1) Isoniazid causes heart looping disorder in zebrafish embryos by the induction of oxidative stress; 2) Identification of Key genes and pathways in abdominal aortic aneurysm by integrated bioinformatic analysis; 3) MiR-124 attenuates doxorubicin-induced cardiac injury via inhibiting p66Shc-mediated oxidative stress; 4) Neutrophil to lymphocyte ratio as a prognostic marker for in-hospital mortality of patients with sepsis: A secondary analysis based on a single-center, retrospective, cohort study.

Collection Overview

Heart failure is a clinical syndrome of cardiac insufficiency caused by various heart diseases and is also the final common pathway of many cardiovascular diseases. The successful establishment of animal models is the most important step in studying pathophysiological processes and molecular mechanisms. We want to summarize the current methods of heart failure and propose some new, stable, economical, and practical models. They are generally categorized into surgery operations (electrode implantation, arteriovenous fistula operation, heart valve destruction, transverse aortic constriction, and left anterior descending ligation), drug supplements (catecholamines, angiotensin, doxorubicin, and other cardiotoxic drugs) and genetic engineering (gene overexpression or silencing).